NL-OMON38320
Completed
Phase 2
Phase II study of 18 F fluorothymidine Positron Emission Tomography (FLT-PET) in the follow up of glioblastoma multiforme (GBM) patients treated with combined radiotherapie and chemotherapy - Using FLT-PET in the follow up of glioblastoma multiforme patients
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- braintumor
- Sponsor
- niversitair Medisch Centrum Groningen
- Enrollment
- 30
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with histologically confirmed newly diagnosed glioblastoma multiforme (World Health Organization \[WHO] grade IV astrocytoma) with indication for radiotherapy and concomitant TMZ followed by adjuvant TMZ.
- •Patients must have clinically and radiographically documented measurable disease. Conventional MRI post surgery must be performed within 28 days prior to start of combined treatment.
- •Absence of inability to undergo MRI or PET scanning
- •Patients \>18 years of age
- •WHO performance status of 2 or less
- •Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow\-up schedule; those conditions should be discussed with the patient before registration in the trial
- •Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.
Exclusion Criteria
- •Are formulated as 'no existence of' in inclusion criteria
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Evaluation of 3'-deoxy-3'-[18F]fluorothymidine -PET and diffusion weighted imaging -MRI in patients with early stage non-small cell lung cancer treated with a platinum-based doublet as preoperative chemotherapy.Lungcancernon-small cell lung cancer10038666NL-OMON42040European Organisation for Research in Treatment of Cancer (EORTC)4
Active, not recruiting
Not Applicable
18F-Fluorothymidine Positron Emission Tomography as an early predictor of response to neoadjuvant therapy in patients with locally advanced breast carcinoma - NDBreast carcinoma classified as cT1b,c, T2, T3, or cT4 a-c, cN0-2, N3, M0MedDRA version: 9.1Level: HLTClassification code 10006289EUCTR2010-020472-34-ITISTITUTO EUROPEO DI ONCOLOGIA
Completed
Phase 2
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone MetastasesHormone-Resistant Prostate CancerMetastatic Malignant Neoplasm in the BoneRecurrent Prostate CarcinomaStage IV Prostate CancerNCT00936975National Cancer Institute (NCI)18
Active, not recruiting
Early Phase 1
18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical CystectomyBladder CancerUrothelial CarcinomaNCT04018053Brigham and Women's Hospital16
Recruiting
Phase 2
Feasibility of FMISO in Brain TumorsMalignant Brain NeoplasmNCT03649880OHSU Knight Cancer Institute50